1998-00

   Muller M, Rastelli C, Ferri P, Jansen B, Breiteneder H, Eichler HG. "Transdermal penetration of diclofenac after multiple epicutaneous administration". J Rheumatol 1998 ;25:1833-1836. PubMed
 
   B. Saletu, P. Anderer, A. Assandri, W. Orazse, M. Abu-Bakr, E. Lindeck-Pozza, G.M. Saletu-Zyhlarz: "Proving central effects of the nutraceutical and supplementary substance S-adenosyl-L-methionine (ademetionine) by pharmaco-EEG mapping". Textbook of the training course of the 11th Biennial Congress of Pharmaco EEG, Vienna 2000.

   Jansen B, Graselli U, Dallinger S, Kiss B, Wacheck V, Schlagbauer-Wadl H, Assandri A, Muller M. "Pharmacokinetics and pharmacodynamics of the novel H1-receptor antagonist emedastine in healthy volunteers". Eur J Clin Pharmacol 2000 Feb-;55:837-41. PubMed

2001

   Herranz U, Rusca A, Assandri A., "Emedastine-ketoconazole: pharmacokinetic and pharmacodynamic interactions in healthy volunteers". Int J Clin Pharmacol Ther 2001;39:102-9. PubMed

   Joukhadar C, Herranz U, Pernerstorfer T, Assandri A, Klein N, Schrolnberger C, Lackner E, Eichler HG, Muller M; "Pharmacokinetics of emedastine difumarate, a new anti-histaminic agent in patients with renal impairment". Eur J Clin Pharmacol 2001 Mar;56(12):905-10. PubMed

2002

   Brunner M, Kletter K, Assandri A, Ermanno Corrado M, Eichler HG, Muller M. "Pharmacokinetic and mass balance study of unlabelled and (14)C-labelled emedastine difumarate in healthy volunteers." Xenobiotica 2002;32:761-70. PubMed

   Saletu B, Anderer P, Linzmayer L, Semlitsch HV, Lindeck-Pozza E, Assandri A, di Padova C, Saletu-Zyhlarz GM. "Pharmacodynamic studies on the central mode of action of S-adenosyl-L-methionine infusions in elderly subjects, utilizing EEG mapping and psychometry", J Neural Transm 2002 ;109:1505-26. PubMed

   P. Anderer, B. Saletu, HV Semlitsch, A. Assandri, C. Di Padova, W. Prause, E. Lindeck-Pozza, G.M. Saletu-Zyhlarz " Acute and sub-acute, double-blind, placebo-controlled studies on the effects of S-adenosyl-L-methionine on information" processing by ERP-mapping and LORETA International Congress Series 1232 (2002)237-241.

   Saletu-Zyhlarz GM, Anderer P, Linzmayer L, Semlitsch HV, Assandri A, Prause W, Hassan Abu-Bakr M, Lindeck-Pozza E, Saletu B. Visualizing central effects of S-adenosyl-L-methionine (SAMe), a natural molecule with antidepressant properties, by pharmaco-EEG mapping. Int J Neuropsychopharmacol 2002 Sep;5(3):199-215. PubMed

2003

   Brunner M, Assandri R, Kletter K, Tschurlovits M, Corrado ME, Villa R, Eichler HG, Muller M. "Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation". Aliment Pharmacol Ther. (2003). 17, 395-402. PubMed

   Brunner M, Greinwald R, Kletter K, Kvaternik H, Corrado ME, Eichler HG, Muller M. "Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers". Aliment Pharmacol Ther. (2003) 17 1163-9. PubMed

2004

   Horak F, Stübner P, Zieglmayer R, Kavina A, Corrado EM, Assandri A and Mion A. "Study of the therapeutic efficacy and safety of emedastine difumarate versus cetirizine in the treatment of seasonal allergic rhinitis". Arzneim.-Forsch./Drug Res. 54, 666-672(2004). PubMed

   Corrado EM, Radicioni MM, Hartwig J, Assandri A, Oldeman HG, and Mion A. "Clinical study of the therapeutic efficacy and safety of emedastine difumarate versus terfenadine in the treatment of seasonal allergic rhinitis". Arzneim.-Forsch./Drug Res. 54, 660-665(2004). PubMed

   Poli G, Mariotti F, Corrado ME, Acerbi D. "A tolerability and pharmacokinetic study of a new injectable formulation of disodium clodronate in healthy female volunteers". Eur J Drug Metab Pharmacokinet. 2004, 29,145-52. PubMed

2005

   Arnold O, Saletu B, Anderer P, Assandri A, di Padova C, Corrado M, Saletu-Zyhlarz GM. "Double-blind, placebo-controlled pharmacodynamic studies with a nutraceutical and a pharmaceutical dose of ademetionine (SAMe) in elderly subjects, utilizing EEG mapping and psychometry". Eur Neuropsychopharmacol. (2005)15, :533-43. PubMed

   Brunner M, Ziegler S, Di Stefano AF, Dehghanyar P, Kletter K, Tschurlovits M, Villa R, Bozzella R, Celasco G, Moro L, Rusca A, Dudczak R, Muller M. "Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation". Br J Clin Pharmacol. (2005) ,61, 31-38. PubMed

   Valle M, Barbanoj MJ, Donner A, Izquierdo I, Herranz U, Klein N, Eichler HG, Muller M, Brunner M. "Access of HTB, main metabolite of triflusal, to cerebrospinal fluid in healthy volunteers". Eur J Clin Pharmacol. (2005), 61, 103-11. PubMed

2006

   Stuebner P, Horak F, Zieglmayer R, Arnaiz E, Leuratti C, Perez I, Izquierdo I. "Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber". Ann Allergy Asthma Immunol. (2006), 96,37-44. PubMed

   Bauer M, Langer O, Dal-Bianco P, Karch R, Brunner M, Abrahim A, Lanzenberger R, Hofmann A, Joukhadar C, Carminati P, Ghirardi O, Piovesan P, Forloni G, Corrado ME, Lods N, Dudczak R, Auff E, Kletter K, Muller M. "A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease". Clin Pharmacol 2006 80(3):216-27. PubMed

2007

   Minghetti P, Cilurzo F, Pagani S, Casiraghi A, Assandri R, Montanari L "Formulation study of oxybutynin patches". Pharm Dev Technol. 2007;12(3):239-46. PubMed

   Poli G, Acerbi D, Pennini R, Soliani Raschini A, Corrado ME, Eichler HG, Eichler I, "Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi, Paediatr Drugs", 2007;9 Suppl 1:3-9. PubMed

2008

  Anderer P., Saletu B., Wolzt M., Culic S., Assandri A., Nannipieri F., Rosini S. and Saletu-Zyhlarz G.M., "Double-blind, placebo-controlled, multiple-ascending-dose study on the effects of ABIO-08/01, a novel anxiolytic drug, on perception and cognition, utilizing event-related potential mapping and low-resolution brain electromagnetic tomography" Hum. Psychopharmacol. 2008 Apr;23(3):243-54. PubMed

   Leitner J.M., Mayr F.B., Spiel A.O., Firbas C., Savulsky C., Mis R., Corrado M.E. and  Jilma B., The pharmacokinetics and pharmacodynamics of a new sustained release leuprolide acetate depot compared to the market reference. Int. J. Clin. Pharmacol. and Ther. 2008; 46 (8): 407-414. PubMed

   Cerabolini R., Boissard G., Buonfiglio T., Savorelli M.P., "Children faces with the aerosol therapy. Compliance's inhalation therapy observation (study) when aerosol is administered with a device equipped with educational games for children 5-8 years." Ricerche di Psicologia, 3/2008.

   Corrado M.E. "CPD - A participant's perspective", Quasar, Journal of the British Association of Quality Assurance, BARQA, July 2008; 104: 32-33.

2009

   Rusca A, Di Stefano AF, Doig MV, Scarsi C, Perucca E. "Relative bioavailability and pharmacokinetics of two oral formulations of docosahexaenoic acid/eicosapentaenoic acid after multiple-dose administration in healthy volunteers." Eur J Clin Pharmacol. 2009 Jan 16. PubMed

   Lindstedt R, Ruggiero V, D'Alessio V, Manganello S, Petronzelli F, Stasi MA, Vendetti S, Assandri A, Carminati P, De Santis R. "The immunosuppressor st1959, a 3,5-diaryl-s-triazole derivative, inhibits T  cell activation by reducing NFAT nuclear residency." Int J Immunopathol Pharmacol. 2009 Jan-Mar;22(1):29-42. PubMed

   Saletu-Zyhlarz GM, Anderer P, Wolzt M, Semlitsch HV, Assandri A, Nessi P, Nannnipieri F, Rosini S, Rosini S, Saletu B "Double-Blind, Placebo-Controlled, Multiple-Ascending-Dose Study on the pharmacodynamics of ABIO-08/01, a New CNS Drug with Potential Anxiolytic Activity. 1. EEG Mapping, Psychometric and Tolerability Findings." Neuropsychobiology. 2009 Apr 10;59(2):100-109. PubMed

   Saletu B, Anderer P, Wolzt M, Nosiska D, Assandri A, Noseda E, Nannipieri F, Saletu-Zyhlarz GM "Double-Blind, Placebo-Controlled, Multiple-Ascending-Dose Study on the Pharmacodynamics of ABIO-08/01, a New CNS Drug with Potential Anxiolytic Activity. 2. EEG-Tomography Findings Based on LORETA (Low-Resolution Brain Electromagnetic Tomography)" Neuropsychobiology. 2009 Apr 10;59(2):110-122. PubMed

  Shore N.D., Savulsky C., Mis R., Karlin G., Marberger M., Leuratti C., Kaisary A. "Phase III efficacy and safety trial of a new leuprolide acetate 3.75 mg depot formulation in prostate cancer patients." Publication-only abstracts issured by ASCO Annual '09 Meeting.

  Corrado M.E. "Great Expectations: CROs Face Change in Italy", Applied Clinical Trials, November 2009; 18 (11): 50-54.

2010

   Corrado M.E. Great Expectations: changes for contract research organisations (CROs) in Italy Publication. Quasar, Journal of the British Association of Quality Assurance, BARQA, April 2010; 111: 24-26.

   Marberger M, Kaisary AV, Shore ND, Karlin GS, Savulsky C, Mis R, Leuratti C, Germa JR. "Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study." Clin Ther. 2010 Apr;32(4):744-57. PubMed

   Rosignoli MT, Di Loreto G, Dionisio P. "Effects of prulifloxacin on cardiac repolarization in healthy subjects: a randomized, crossover, double-blind versus placebo, moxifloxacin-controlled study". Clin Drug Investing. 2010;30(1):5-14.

   G.R. D'Haens, Á. Kovács, P. Vergauwe, F. Nagy, T. Molnár, Y. Bouhnik, W. Weiss, H. Brunner, A. Lavergne-Slove, D. Binelli, A.F.D. Di Stefano, and P. Marteau. Clinical trial: "Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis". Journal of Crohn's and Colitis Volume 4, Issue 2, June 2010, Pages 153-160. ScienceDirect